These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 35703556)

  • 1. Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants.
    Chen CP; Huang KA; Shih SR; Lin YC; Cheng CY; Huang YC; Lin TY; Cheng SH
    Microbiol Spectr; 2022 Aug; 10(4):e0074322. PubMed ID: 35703556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous Measurement of IgM and IgG Antibodies to SARS-CoV-2 Spike, RBD, and Nucleocapsid Multiplexed in a Single Assay on the xMAP INTELLIFLEX DR-SE Flow Analyzer.
    Cameron A; Bohrhunter JL; Porterfield CA; Mangat R; Karasick MH; Pearson Z; Angeloni S; Pecora ND
    Microbiol Spectr; 2022 Apr; 10(2):e0250721. PubMed ID: 35389244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
    Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
    mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
    Ikemura N; Taminishi S; Inaba T; Arimori T; Motooka D; Katoh K; Kirita Y; Higuchi Y; Li S; Suzuki T; Itoh Y; Ozaki Y; Nakamura S; Matoba S; Standley DM; Okamoto T; Takagi J; Hoshino A
    Sci Transl Med; 2022 Jun; 14(650):eabn7737. PubMed ID: 35471044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma.
    Fenwick C; Turelli P; Pellaton C; Farina A; Campos J; Raclot C; Pojer F; Cagno V; Nusslé SG; D'Acremont V; Fehr J; Puhan M; Pantaleo G; Trono D
    Sci Transl Med; 2021 Aug; 13(605):. PubMed ID: 34257144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Choe PG; Hong J; Park J; Chang E; Kang CK; Kim NJ; Lee CH; Park WB; Oh MD
    J Infect Dis; 2022 Sep; 226(7):1224-1230. PubMed ID: 35299253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-dependent NK-cell and neutralizing antibody responses against the Spike protein of Wuhan-Hu-1 and Omicron BA.1 SARS-CoV-2 variants in vaccinated experienced and vaccinated naïve individuals.
    Albert E; Fernández-Soto D; Giménez E; Casanovas JM; Zulaica J; Álvarez-Rodríguez B; Rusu L; Geller R; Reyburn HT; Navarro D
    J Med Virol; 2023 Jul; 95(7):e28900. PubMed ID: 37403730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants.
    Li B; Zhao Y; Wu X; Wu H; Tang W; Yu X; Mou J; Tan W; Jin M; Li W; Zhang Q; Liu M
    ACS Nano; 2023 Apr; 17(7):7017-7034. PubMed ID: 36971310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 - A Comprehensive Analysis.
    Meyer B; Martinez-Murillo PA; Lemaitre B; Blanchard-Rohner G; Didierlaurent AM; Fontannaz P; Eugercios Manzanas C; Lambert PH; Loevy N; Kaiser L; Sartoretti J; Tougne C; Villard J; Huttner A; Siegrist CA; Eberhardt CS
    Front Immunol; 2022; 13():841009. PubMed ID: 35585978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.
    Morinaga Y; Tani H; Terasaki Y; Nomura S; Kawasuji H; Shimada T; Igarashi E; Saga Y; Yoshida Y; Yasukochi R; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Fujimura T; Ishida Y; Oishi K; Yamamoto Y
    Microbiol Spectr; 2021 Dec; 9(3):e0056021. PubMed ID: 34851163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing and enhancing monoclonal antibodies in SARS-CoV-2 convalescent patients: lessons from early variant infection and impact on shaping emerging variants.
    Coutant F; Touret F; Pin JJ; Alonzo M; Baronti C; Munier S; Attia M; de Lamballerie X; Ferry T; Miossec P
    Emerg Microbes Infect; 2024 Dec; 13(1):2307510. PubMed ID: 38240255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omicron infection increases IgG binding to spike protein of predecessor variants.
    Mahalingam G; Periyasami Y; Arjunan P; Subaschandrabose RK; Mathivanan TV; Mathew RS; Devi RKT; Premkumar PS; Muliyil J; Srivastava A; Moorthy M; Marepally S
    J Med Virol; 2023 Feb; 95(2):e28419. PubMed ID: 36546401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern.
    Valdovino-Navarro BJ; Dueñas S; Flores-Acosta GI; Gasperin-Bulbarela J; Bernaldez-Sarabia J; Cabanillas-Bernal O; Cervantes-Luevano KE; Licea-Navarro AF
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.